Literature DB >> 21956430

Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy.

Edwin O Onkendi1, Sarah Y Boostrom, Michael G Sarr, Michael B Farnell, David M Nagorney, John H Donohue, Michael L Kendrick, Kaye M Reid Lombardo, Michael G Haddock, Florencia G Que.   

Abstract

AIM: To evaluate the role of neoadjuvant chemoradiation therapy and rescue surgery in the management of unresectable or recurrent duodenal adenocarcinoma.
METHODS: Retrospective review of all adults treated with neoadjuvant therapy and rescue surgery for locally unresectable or locally recurrent duodenal adenocarcinoma from 1994 to 2010.
RESULTS: Ten patients received various forms of neoadjuvant therapy prior to operative exploration for potential resection. Six patients presented with locally unresectable disease, while four had local recurrences. Six patients had vascular encasement, three had retroperitoneal extension with vascular invasion, and one had invasion of surrounding organs. Of the six patients with locally advanced disease, preoperative therapy consisted of chemotherapy alone (3) or chemoradiotherapy (3). Of the four patients with local recurrences, preoperative therapy consisted of chemotherapy alone (1), chemoradiotherapy alone (1), chemoradiotherapy after chemotherapy (1), and chemoradiotherapy followed by combination chemotherapy (1). Nine of ten patients became resectable after neoadjuvant therapy. Clinically, two patients had complete responses, and four had partial responses. Histopathology revealed complete pathologic response in two patients and near-complete pathologic response in one (<1 mm of residual disease). Currently, five patients are alive (range 18-83 months postoperatively). All have no evidence of disease.
CONCLUSION: Neoadjuvant therapy may convert locally unresectable duodenal adenocarcinoma to resectable disease with subsequent prolonged survival.

Entities:  

Mesh:

Year:  2011        PMID: 21956430     DOI: 10.1007/s11605-011-1667-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  9 in total

1.  Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.

Authors:  Chris R Kelsey; John W Nelson; Christopher G Willett; Junzo P Chino; Robert W Clough; Johanna C Bendell; Douglas S Tyler; Herbert I Hurwitz; Michael A Morse; Bryan M Clary; Theodore N Pappas; Brian G Czito
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-06       Impact factor: 7.038

2.  What prognostic factors are important in duodenal adenocarcinoma?

Authors:  F G Bakaeen; M M Murr; M G Sarr; G B Thompson; M B Farnell; D M Nagorney; D R Farley; J A van Heerden; L M Wiersema; C D Schleck; J H Donohue
Journal:  Arch Surg       Date:  2000-06

3.  Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.

Authors:  Bouthaina S Dabaja; Dima Suki; Barbara Pro; Mark Bonnen; Jaffer Ajani
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

4.  Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.

Authors:  L Coia; J Hoffman; R Scher; J Weese; L Solin; L Weiner; B Eisenberg; A Paul; G Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-08-30       Impact factor: 7.038

5.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

6.  Primary carcinoma of the duodenum.

Authors:  A Alwmark; A Andersson; A Lasson
Journal:  Ann Surg       Date:  1980-01       Impact factor: 12.969

7.  Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study.

Authors:  R S Yeung; J L Weese; J P Hoffman; L J Solin; A R Paul; P F Engstrom; S Litwin; M J Kowalyshyn; B L Eisenberg
Journal:  Cancer       Date:  1993-10-01       Impact factor: 6.860

8.  Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival.

Authors:  Aaron Struck; Thomas Howard; Elena G Chiorean; Jeffrey M Clarke; Robert Riffenburgh; Higinia R Cardenes
Journal:  J Surg Oncol       Date:  2009-08-01       Impact factor: 3.454

Review 9.  Primary duodenal adenocarcinoma.

Authors:  Mario Solej; Silvia D'Amico; Gabriele Brondino; Marco Ferronato; Mario Nano
Journal:  Tumori       Date:  2008 Nov-Dec
  9 in total
  12 in total

1.  Perioperative Complications and Outcomes after Intestinal Autotransplantation for Neoplasms Involving the Superior Mesenteric Artery.

Authors:  Guosheng Wu; Qingchuan Zhao; Xiaohua Li; Mian Wang; Hao Sun; Jingson Zhang; Zengshan Li; Jianyong Zheng; Mengbin Li; Daiming Fan
Journal:  J Gastrointest Surg       Date:  2019-04-01       Impact factor: 3.452

2.  Adenocarcinoma of the third duodenal portion: Case report and review of literature.

Authors:  Federico Sista; Giuseppe De Santis; Antonio Giuliani; Emanuela Marina Cecilia; Federica Piccione; Laura Lancione; Sergio Leardi; Gianfranco Amicucci
Journal:  World J Gastrointest Surg       Date:  2012-01-27

Review 3.  Small bowel adenocarcinomas--existing evidence and evolving paradigms.

Authors:  Kanwal Raghav; Michael J Overman
Journal:  Nat Rev Clin Oncol       Date:  2013-07-30       Impact factor: 66.675

4.  Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma.

Authors:  Suguru Yamashita; Michael J Overman; Huamin Wang; Jun Zhao; Masayuki Okuno; Claire Goumard; Ching-Wei Tzeng; Michael Kim; Jason B Fleming; Jean-Nicolas Vauthey; Matthew H Katz; Jeffrey E Lee; Claudius Conrad
Journal:  Ann Surg Oncol       Date:  2017-10-04       Impact factor: 5.344

Review 5.  Primary small-bowel malignancy: update in tumor biology, markers, and management strategies.

Authors:  Santosh Shenoy
Journal:  J Gastrointest Cancer       Date:  2014-12

6.  Helical tomotherapy for duodenal adenocarcinoma in an elderly patient: A case report.

Authors:  Valentina Lancellotta; Giuseppe Russo; Marco Lupattelli; Martina Iacco; Elisabetta Perrucci; Claudio Zucchetti; Lorenzo Falcinelli; Cynthia Aristei
Journal:  World J Gastrointest Oncol       Date:  2017-02-15

7.  Radical resection of a primary unresectable duodenal cancer after chemotherapy using S-1 and cisplatin: report of a case.

Authors:  Masaru Kanehira; Yasuro Futagawa; Kenei Furukawa; Hiroaki Shiba; Tadashi Uwagawa; Katsuhiko Yanaga
Journal:  Surg Case Rep       Date:  2017-02-21

8.  Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma.

Authors:  Carlos Velandia; Rafael Delgado Morales; Carlos Coello; Armando Gil Mendoza; Gabriel Pérez; Emperatriz Aguero
Journal:  Ecancermedicalscience       Date:  2018-03-05

9.  A complete response to capecitabine and oxaliplatin chemotherapy in primary duodenal carcinoma with liver and nodal metastases: a case report.

Authors:  Seita Hagihara; Tetsunosuke Shimizu; Yoshihiro Inoue; Mitsuhiro Asakuma; Fumitoshi Hirokawa; Kohei Taniguchi; Michihiro Hayashi; Kazuhisa Uchiyama
Journal:  Surg Case Rep       Date:  2018-09-29

10.  Tumour stage and resection margin status are independent survival factors following partial pancreatoduodenectomy for duodenal adenocarcinoma.

Authors:  Kulbir Mann; T Gilbert; S Cicconi; R Jackson; P Whelan; F Campbell; C Halloran; J Neoptolemos; P Ghaneh
Journal:  Langenbecks Arch Surg       Date:  2019-04-10       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.